View Mobile Friendly Conference List »

Setting new standards in information exchange for the pharmaceutical and biotech industry


Halozyme Announces Partnerships with BMS and Roche

  • October 5, 2017

  • Halozyme announced two partnerships in September, with BMS and Roche, around Halozyme’s ENHANZE® drug-delivery technology.

    BMS and Halozyme announced a global collaboration and license agreement to develop subcutaneously administered BMS immuno-oncology medicines using Halozyme’s ENHANZE® drug-delivery technology. The same day, Halozyme announced it licensed its ENHANZE® drug-delivery technology to Roche for exclusive development of an undisclosed therapeutic target.

    “The Halozyme ENHANZE technology is based on a proprietary recombinant human hyaluronidase enzyme (rHuPH20) that temporarily degrades hyaluronan — a glycosaminoglycan or chain of natural sugars in the body — to aid in the dispersion and absorption of other injected therapeutic drugs. This technology may allow for more rapid delivery of large volume injectable medications, such as medications that are currently delivered intravenously, through subcutaneous delivery.”

    Read more about the BMS agreement.

    Learn about the Roche agreement.

    Halozyme’s Dr Kenneth A. Schultz is speaking at the 7th annual PODD event in Boston (Oct 19-20). Also speaking will be BMS’s Dr Srini Sridharan and PODD is chaired by Roche’s Dr Barbara Lueckel.